A carregar...
BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
BRAF mutations have been identified as targetable, oncogenic mutations in many cancers. Given the paucity of treatments for primary brain tumors and the poor prognosis associated with high-grade gliomas, BRAF mutations in glioma are of considerable interest. In this review, we present the spectrum o...
Na minha lista:
| Publicado no: | Cancers (Basel) |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6769482/ https://ncbi.nlm.nih.gov/pubmed/31466300 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11091262 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|